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ical diseases by using TEE and to assess if the D-dimer test can
predict the presence of a central venous catheter-related throm-
bus. We assessed 37 patients with various hematological diseases
(18 AML, 8 NHL, 6 ALL, 2 MM, 1 HL, 1 primary amiloidosis,
and 1 MDS). Mean age was 37 years. Mean time with catheter
was 2.66 months. Fourteen of thirty-seven patients were trans-
planted. Thrombus was found in 8 of 37 patients (21.6%).
Thrombus incidence in transplanted group was 28.57% (4/14).
Thirty-four of the patients (91.9) were asymptomatic. No rela-
tion was found between thrombus and D-dimer levels (P 
.071). The time with catheter was not related with the presence
of thrombus also (P  .328). Our ﬁndings showed that TEE is
a useful method in evaluating the presence of thrombus at the
tip of central venous catheters, so it can be useful for the
prediction of complications due to thrombus before catheter
removal. D-dimer shows tendency to be useful in predicting the
presence of a thrombus.
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Atypical mycobacterium infections are uncommon in children
undergoing HSCT compared to solid organ transplant recipi-
ents or HIV patients, though more prevalent than in the general
population. Improvements in laboratory diagnostic methods
have led to more accurate and timely identiﬁcation of mycobac-
terium isolates. Diagnosis of non-tuberculus mycobacterium
(NTM) infection in immunocompromised children is difﬁcult
due to non-speciﬁc, diverse clinical manifestations. We report 3
pediatric patients who underwent related donor HSCT from
2002 to 2005 and developed deﬁnite NTM infections in the
setting of fever of unknown origin. Patient 3 was transplanted at
Fred Hutchinson Cancer Research Center, received donor lym-
phocyte infusion at CMH and was re-grafted at Washington
University Medical Center. CD4 counts were 	200/l at the
time of diagnosis. Of note, the CD4 count had just recovered in
patient 2 as has been reported in patients with AIDS developing
atypical mycobacterium osteomyelitis. All patients were immu-
nosuppressed at the time of NTM diagnosis. Aggresive local
treatment such as debridement followed by bone grafting and
insertion of appropriately coated antibiotic beads was essential
for treatment of NTM osteomyelitis. Patient 3 underwent a
second transplant and an alemtuzumab-based reduced intensity
conditioning regimen without NTM prophylaxis and did not
reactivate infection. Outcomes of NTM disease were all favor-
able after appropriate antimicrobial therapy. Susceptibility test-
ing of isolates with MIC was very helpful in choosing appropri-
ate outpatient treatment. The combination of newer macrolides,
ethambutol, rifabutin, and ﬂuoroquinolones appears to have
greater in vivo activity and to provide improved eradication of
bacteria compared to single agents. Concomitant surgical de-
bridement and removal of the central venous catheter when
indicated was essential. We conclude: (1) NTM infection can
cause fever of unknown origin in HSCT patients. (2) NTM
infection can be successfully treated in the outpatient clinic with
antimicrobials chosen according to susceptibility testing of pa-
tient isolates. (3) Local treatment such as catheter removal,
excisional biopsy, and surgical debridement are critical and can
be performed without delayed wound healing or the necessity of
skin grafting in the setting of active skin GVHD. (4) Subsequent
second HSCT can be performed without prophylaxis provided
that the prior NTM infection has been adequately treated (Ta-
ble 1).
Table 1. Patient Characteristics and Outcomes
Category Pt. 1 Pt. 2 Pt. 3
Diagnosis SCID AML IPEX
Age at HSCT 6 months 16 years 2 years
Stem Cells and
Match
maternal PBSC, 3
of 6
maternal PBSC, 3
of 6
BM, 6 of 6 sister
Preparation Flu/ATG Flu/TBI/Melphalan/
ATG
1: Flu/TBI; 2:
Campath/Flu/
Melphalan
GVHD prophylaxis/
treatment
TCD TCD 1: Tacrolimus,
MMF; 2:
Tacrolimus,
steroid
Vital Status alive alive alive
Engraftment full donor
chimerism
full donor
chimerism
1: mixed
chimerism; 2:
mixed chimerism
GVHD grade II acute grade II acute none
A. Mycobacterium
site
central line, lung tibia subcutaneous
Species M. chelonae/
abscessus
M. avium complex M.
chelonae/abscessus
Evaluation blood culture, CT
scan, lung biopsy
CT scan, MRI, bone
aspiration
CT scan, MRI,
excisional biopsy
Onset 6 months 39 days 22 months
Treatment &
Outcome
catheter removal,
ciprofloxacin,
azithromycin,
linezolid  6 wks;
resolved
azithromycin,
ethambutol,
linezolid  8
months,
debridement,
bone graft with
antibiotic beads
surgical excision;
cefoxitin,
azithromycin,
linezolid  8
months
Abbreviations: SCID, common gamma chain X-linked severe
combined immunodeﬁciency; AML, acute myelogenous leuke-
mia; IPEX, immune dysregulation, polyendocrinopathy, enter-
opathy, X-linked; PBSC, peripheral blood stem cells; BM, bone
marrow; Flu, ﬂudarabine; ATG, anti-thymocyte globulin; TBI,
total body irradiation; TCD, T-cell depletion; MMF, mycophe-
nolate mofetil
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Velafermin (CG53135-05) or recombinant human ﬁbroblast
growth factor-20 (rhFGF-20) protein is under investigation for the
treatment of active oral mucositis (OM). OM is a commonly
occurring side effect of high-dose chemotherapy (HDCT) in pa-
tients (pts) undergoing autologous hematopoietic stem cell trans-
plant (AHSCT) and in leukemia pts receiving CT. Pharmacology
studies demonstrated that treatment of velafermin to animals with
active OM for 2, 3, or 4 consecutive days resulted in a signiﬁcant
reduction in duration of clinically relevant OM compared with
animals in the vehicle treated control group. Previous clinical
studies showed that velafermin was generally well tolerated as a
single dose regimen up to 0.2 mg/kg dose level. The objectives of
this Phase I trial are to evaluate the safety, tolerability and phar-
macokinetics (PK) of velafermin when administered as three daily
doses via intravenous (IV) infusion to pts who develop oral mu-
cositis after receiving HDCT. OM and diarrhea status are evalu-
ated using the World Health Organization (WHO) grading sys-
tem. Approximately 9–12 pts receiving AHSCT following myelo-
ablative CT or leukemia pts receiving CT, age 18 years and older,
are to be enrolled when Grades 1 or 2 OM is observed. Velafermin
treatment is initiated within 24 hours after OM is observed. Three
pts will be treated at each dose level based on tolerability and
recruitment parameters. Pts will receive velafermin at 0.03, 0.1, or
0.2 mg/kg/day for 3 consecutive days. Pt follow-up will be contin-
ued for approximately 60 days following infusion of velafermin.
The 3 pts in the ﬁrst cohort receiving 0.03 mg/kg tolerated mul-
tiple doses of velafermin well with no complaints or adverse events
(AE) during or immediately after infusion. Dose escalation deci-
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